One To Watch

Agios Pharmaceuticals

Company Overview

A Cambridge-based rare-disease biopharmaceutical company building a hematology franchise around its first-in-class pyruvate kinase activator mitapivat, now expanding into immune thrombocytopenia via a newly licensed SYK inhibitor. Agios (Nasdaq: AGIO) roots its science in cellular metabolism — specifically how red blood cell enzyme defects drive hemolytic anemia — and has translated that insight into two approved products. A June 2026 deal for cevidoplenib, a next-generation oral SYK inhibitor for ITP, signals the company is deliberately widening its rare-hematology perimeter beyond the PK-activator franchise.

Headquarters and Global Presence

Agios is headquartered in Cambridge, Massachusetts, with commercial operations active in the U.S. and, following the May 2026 European Commission approval of PYRUKYND for thalassemia, across EU member states. The company trades on the Nasdaq under the ticker AGIO and carried approximately $1.045 billion in cash and marketable securities as of March 31, 2026.

Founding and History

Agios was founded in 2007 and went public in July 2013, originally built around cancer metabolism and IDH-mutant oncology. The strategic pivot came in April 2021, when Agios closed the $1.8 billion sale of its oncology business — including TIBSOVO and its IDH portfolio — to Servier, reorienting entirely toward rare genetically defined diseases. The divestiture continues to pay dividends: following the August 2024 FDA approval of vorasidenib by Servier, Agios became entitled to $1.1 billion in payments, including $905 million from monetizing the royalty to Royalty Pharma and a $200 million Servier milestone, while retaining a 15% royalty on U.S. vorasidenib net sales.

Therapy Areas and Focus

Agios is focused squarely on rare hemolytic anemias driven by red blood cell enzyme defects, targeting PK deficiency, alpha- and beta-thalassemia, and sickle cell disease. The unifying logic is that activating pyruvate kinase in deficient red cells corrects the metabolic failure that shortens cell lifespan and drives anemia. The June 2026 addition of cevidoplenib extends the franchise into immune thrombocytopenia, a rare autoimmune bleeding disorder affecting roughly 200,000 patients globally, adding a mechanistically distinct platform targeting autoantibody-driven platelet destruction.

Technology Platforms and Modalities

The anchor platform is PK activation: small-molecule allosteric activators of pyruvate kinase R (PKR) that restore ATP production in red blood cells and reduce hemolysis. Mitapivat was the first approved therapy to work by this mechanism. Tebapivat, a next-generation PKR activator, extends the approach into MDS-associated anemia where PKR dysfunction also plays a role. Cevidoplenib introduces a second modality — oral SYK inhibition — blocking the FcγR signaling cascade that drives autoantibody-mediated platelet destruction in ITP, and is designed to improve on the tolerability and durability limitations of first-generation SYK inhibitors such as fostamatinib.

Key Pipeline and Programs

Mitapivat (PYRUKYND / AQVESME) is a first-in-class oral PKR activator approved by the FDA in February 2022 for PK deficiency on the basis of the ACTIVATE and ACTIVATE-T Phase III trials. The FDA approved the thalassemia indication in December 2025 (branded AQVESME), and the European Commission followed in May 2026, making PYRUKYND the only approved medicine for the broad thalassemia population across all EU member states. On May 12, 2026, Agios submitted a supplemental NDA seeking U.S. accelerated approval in sickle cell disease, citing hemoglobin-response data from the RISE UP Phase III trial — though the trial's co-primary endpoint of annualized pain crisis rate did not reach statistical significance, a complication the FDA review will need to navigate.

Tebapivat is a next-generation oral PKR activator in Phase IIb development for lower-risk MDS-associated anemia, targeting a prevalent and poorly served population where erythropoiesis-stimulating agents frequently fail.

Cevidoplenib is an oral SYK inhibitor licensed from South Korea's Oscotec in June 2026 ($25 million upfront; up to $140 million in milestones) for immune thrombocytopenia. Agios projects peak U.S. sales potential of up to $1 billion and plans to advance the asset across up to three indications in the U.S. and Europe.

Recent Developments

The twelve months to mid-2026 have been the busiest in Agios' post-divestiture history. The FDA approved mitapivat for thalassemia in December 2025, the European Commission followed in May 2026, and an sNDA for sickle cell disease was filed in May 2026 — three regulatory events inside seven months. The RISE UP Phase III sickle cell readout delivered a mixed verdict: the hemoglobin-response co-primary endpoint was met and hemolysis markers improved, but pain crisis rate did not reach significance, a finding the company is presenting in full at EHA 2026 in Stockholm (June 11-14). On June 1, 2026, Agios announced the cevidoplenib license from Oscotec, adding an ITP asset and diversifying beyond PK activation for the first time. Q1 2026 product revenue of approximately $20.7 million was up 138% year over year, primarily on the U.S. thalassemia launch.

Key Personnel

Brian Goff serves as Chief Executive Officer, leading the company through its commercial expansion across multiple hematology indications. Jacqualyn Fouse, formerly a board member, was appointed CEO in June 2024 to replace David Schenkein — the research context indicates a subsequent leadership configuration with Goff at the helm; Schenkein moved to executive chairman at the time of that transition. The company has not publicly named a Chief Scientific Officer in available filings, though pipeline breadth across three approved or pending indications and two mechanistic platforms reflects an active internal development organization.

Strategic Partnerships

The defining strategic transaction remains the 2021 Servier deal — $1.8 billion upfront for the oncology business, plus retained royalties that generated a further $1.1 billion when vorasidenib was FDA-approved in 2024. The June 2026 Oscotec agreement ($25 million upfront, up to $140 million in milestones, tiered royalties of high single-digit to mid-teen percentages) gives Agios global rights to cevidoplenib; Oscotec retains an option to reclaim South Korean rights following Phase III data. Royalty Pharma participated in the vorasidenib royalty monetization, providing $905 million in proceeds that underpin Agios' current $1 billion-plus cash position.

FAQ Section

The 2021 Servier sale reflected a strategic judgment that the PK-activator platform in rare hematology offered cleaner value creation than competing in the crowded IDH-mutant oncology space. The bet has paid off materially: the August 2024 FDA approval of vorasidenib triggered $1.1 billion in payments to Agios — including $905 million from monetizing the royalty to Royalty Pharma — while the company simultaneously built a commercial rare-disease franchise. Agios enters mid-2026 with roughly $1.045 billion in cash and three approved or pending indications for mitapivat, a position it could not plausibly have reached while funding an oncology pipeline.

Pyruvate kinase R (PKR) is the enzyme that generates ATP in red blood cells during glycolysis; when deficient or dysfunctional, cells produce inadequate energy, become rigid, and are prematurely destroyed in the spleen — the mechanism driving hemolytic anemia in PK deficiency, thalassemia, and sickle cell disease alike. Mitapivat allosterically activates PKR, restoring ATP output and extending red cell lifespan without targeting the underlying genetic defect. The cross-indication applicability is the platform's key commercial attribute: the same mechanism addresses pathophysiology in three distinct, orphan-scale patient populations, and tebapivat is now testing whether MDS-associated anemia represents a fourth.

Fostamatinib (Tavalisse) is the only FDA-approved SYK inhibitor for ITP, but its tolerability profile — including hypertension, diarrhea, and liver enzyme elevations — limits uptake. Cevidoplenib is designed as a next-generation SYK inhibitor with an improved selectivity profile, aiming for better tolerability and more durable platelet responses by more cleanly blocking the FcγR signaling that drives autoantibody-mediated platelet destruction. ITP affects roughly 200,000 patients globally, including approximately 90,000 U.S. adults, and Agios estimates peak U.S. sales potential of up to $1 billion — a plausible number in a market where pricing for chronic rare-disease therapies is substantial and current options remain inadequate for many patients.

The RISE UP data are interpretively awkward: mitapivat met the hemoglobin-response co-primary endpoint and reduced hemolysis markers, but the annualized pain crisis rate — the more clinically and regulatorily weighted endpoint — did not reach statistical significance. Agios filed an sNDA on May 12, 2026, seeking accelerated approval on the hemoglobin-response signal, which is a defensible regulatory pathway but one that implies a confirmatory trial obligation and may not satisfy payers seeking pain-crisis evidence. The detailed data presentation at EHA 2026 will be closely watched for whether any subgroup shows a pain signal that could support a commercial or regulatory narrative.

The immediate pipeline frontier is tebapivat in Phase IIb for lower-risk MDS-associated anemia — a large, underserved population where erythropoiesis-stimulating agents frequently lose efficacy and where a PKR activator addresses a genuinely different biological context than hereditary hemolytic anemia. Cevidoplenib in ITP is the second new territory, introducing autoimmune hematology alongside classical hemolytic anemia. The Oscotec deal structure allows for up to three ITP-adjacent indications, suggesting Agios is thinking about warm autoimmune hemolytic anemia or other autoantibody-driven cytopenias as potential follow-on targets.

Agios is transitioning from a single-product commercial company to a multi-indication one: Q1 2026 product revenue of $20.7 million was up 138% year over year, primarily driven by the U.S. thalassemia launch, and European revenues from the May 2026 EC approval have yet to flow through. The sickle cell sNDA filed in May 2026 is the next regulatory event to watch, likely carrying a PDUFA date in late 2026 or early 2027. Cevidoplenib's Phase III trajectory in ITP will shape the medium-term outlook, while tebapivat Phase IIb data in MDS represent the next internal pipeline readout.

Agios is at a genuinely complex juncture — revenue growing fast, pipeline productive, but key binary events clustering. The watchpoints are:

FDA review of the sickle cell sNDA: whether the agency grants accelerated approval on hemoglobin response alone, given the failed pain-crisis co-primary, is the single biggest near-term regulatory question.
EHA 2026 RISE UP plenary (June 13, 2026): subgroup and biomarker data could substantially shift the sickle cell regulatory and commercial narrative in either direction.
Cevidoplenib Phase III initiation and design in ITP: timelines and endpoint choices will determine whether the $1 billion peak sales estimate is credible or aspirational.
Tebapivat Phase IIb MDS readout: success would open a large non-hereditary anemia opportunity and validate PKR activation in a disease with a very different patient profile.
EU thalassemia commercial ramp: the May 2026 EC approval is recent; European uptake curves will be a key revenue signal in H2 2026 and 2027.

Want to Update your Company's Profile?